Neuronax (now Axoltis pharma)

Neuronax (now axoltis pharma) email format

Verified email-pattern data for Neuronax (Now Axoltis Pharma) is currently limited. You can still use the company insights and contact sections below.
NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs" are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website.
Looking for a particular Neuronax (now Axoltis pharma) employee's phone or email?

Neuronax (Now Axoltis Pharma) Questions

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant